Contact

 

Please contact your
local representative or

info.vi@biotronik.com


 

Orsiro BIOFLOW III

Orsiro currently not available in the US.


Conclusions

  • In this all-comers setting a low TLF rate of 5.1 % was observed within the first 12 months, which demonstrates safety and effectiveness of the Orsiro Hybrid Stent
  • The results observed in this “real world” population demonstrate a low TLF rate comparable to other state of the art DES at 12 months
  • In comparison with other published trials in patients with STEMI, Orsiro shows a low TLF rate

 

Study design 

International, prospective, multi-center open-label,
registry of the Orsiro drug-eluting stent in daily clinical practice

  • Coordinating clinical investigators
    Prof. Johannes Waltenberger,
    M.D. Universitätsklinikum Münster, Germany

    Primary endpoint
  • Target Lesion Failure1 (TLF) at 12 months

    Predefined subgroups
  • Diabetic patients,
  • Small vessels (≤ 2.75 mm),
  • Chronic Total Occlusion
  • Acute MI (STEMI and NSTEMI)

    Post-Hoc
  • B2/C lesions
  • Multivessel disease (MVD)
  • STEMI vs NSTEMI
 

 

 

Sources: 

Presentation, Prof. Johannes Waltenberger, EuroPCR 2015

Presentation, Prof. Johannes Waltenberger, CRT 2015
 

Download:
BIOFLOW-III Study Flyer

 

1 Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI),
Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)
2 Follow-up compliance 95 %

PrintPrint Page MailE-Mail Page Text Size